GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nimacimab   Click here for help

GtoPdb Ligand ID: 14321

Synonyms: JNJ 2463 | JNJ-2463 | RYI-018 | RYI018
Compound class: Antibody
Comment: Nimacimab (RYI-018; Skye Bioscience) is a humanized IgG4 anti-cannabinoid receptor 1 (CB1) monoclonal antibody. It acts to inhibit receptor function and is peripherally restricted.
Based on peptide sequence matches for antibody heavy and light chains between the INN record and patent US10308712B2, nimacimab appears to be clone PIC4-H2-IgG4 therein [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Allen AK. 
Skye’s shares crash down to earth on Phase II obesity loss.
Accessed on 13/01/2026. Modified on 13/01/2026. clinicaltrialsarena.com, https://www.clinicaltrialsarena.com/news/skye-biosciences-nimacimab-obesity-phase-iib-trial/
2. Kretz-Rommel A, Shi L, Ferrini R, Yand T, Xu F, Campion B. (2019)
Antibodies that bind human cannabinoid 1 (CB1) receptor.
Patent number: US10308712B2. Assignee: Bird Rock Bio Sub Inc Ruiyi Biopharmaceutics Technology (shanghai) Co Ltd. Priority date: 27/03/2015. Publication date: 04/06/2019.